X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
1.600
-0.080 (-4.76%)
At close: Aug 1, 2025, 4:00 PM
1.630
+0.030 (1.87%)
After-hours: Aug 1, 2025, 7:30 PM EDT

Company Description

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.

It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections.

It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand.

The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals logo
CountryUnited States
Founded2014
IndustryBiotechnology
SectorHealthcare
Employees143
CEOPaula Ragan

Contact Details

Address:
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
United States
Phone857 529 8300
Websitex4pharma.com

Stock Details

Ticker SymbolXFOR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001501697
CUSIP Number98420X202
ISIN NumberUS98420X1037
Employer ID27-3181608
SIC Code2836

Key Executives

NamePosition
Dr. Paula Ragan Ph.D.Chief Executive Officer, President and Director
Adam S. MostafaChief Financial Officer, Treasurer and Corporate Secretary
Mark Baldry M.B.A.Chief Commercial Officer
Dr. Richard Peters M.D., Ph.D.Founder
Dr. Renato T. Skerlj Ph.D.Founder
Dr. Keith T. Flaherty M.D.Founder and Member of Corporate Advisory Board
Dr. Mary DiBiase Ph.D.Chief Operating Officer
Natasha Thoren Esq.Chief Legal and Compliance Officer
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.Chief Medical Officer
Brian BowersoxVice President of Finance and Corporate Controller

Latest SEC Filings

DateTypeTitle
Jul 18, 2025SCHEDULE 13G/AFiling
Jun 23, 20258-KCurrent Report
Jun 23, 2025424B5Filing
Jun 11, 20258-KCurrent Report
May 1, 202510-QQuarterly Report
May 1, 20258-KCurrent Report
Apr 25, 2025DEF 14AOther definitive proxy statements
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 20258-KCurrent Report
Apr 18, 20258-KCurrent Report